In settling an antitrust lawsuit seeking to block the $28 billion merger of Amgen and Horizon Therapeutics, the Federal Trade Commission has stepped back from what looked like a classic case of overreach. The commission’s logic in trying to block the merger was that there was a hypothetical possibility that Amgen might try to bundle…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
